Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07473713 · ClinicalTrials.gov registry record · Phase 1
Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia
A Phase 1 study, sponsored by Tufts Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT07473713 is a Phase 1 study that is actively recruiting participants, run by Tufts Medical Center. The registered enrollment target is 60 participants.
The verdict
NCT07473713, a Phase 1 study, is actively recruiting participants, sponsored by Tufts Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if veverimer will reduce urinary net acid excretion leading to reduced bone resorption in healthy adults with osteopenia. The main questions it aims to answer are: * How much does each dose of veverimer (vs. placebo) reduce 24-hr urinary net acid excretion. * Describe the safety of veverimer based on changes in serum bicarbonate and potassium. * Assess the changes in bone resorption. * Assess the changes in bone formation. * Explore the effect of veverimer on physical performance. Participants will: * Take veverimer or placebo every day or every other day for 8 weeks * Visit the clinic a total of 8 times (including screening) for checkups and testing * Keep a medication diary tracking each day they take the study drug
Interventions
- OTHER Placebo
- DRUG veverimer daily
- DRUG veverimer every other day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-04-15 |
| Est. Completion | 2028-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07473713
The ClinicalTrials.gov registry entry for NCT07473713 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07473713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07473713 about?
NCT07473713 is a clinical study titled "Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia". The goal of this clinical trial is to learn if veverimer will reduce urinary net acid excretion leading to reduced bone resorption in healthy adults with osteopenia. The main questions it aims to answer are: * How much does each dose of veverimer (vs. placebo) reduce 24-hr urinary net acid excretio...
What is the current status of trial NCT07473713?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2026-04-15. Estimated completion is 2028-05-01.
What interventions are being tested in trial NCT07473713?
The interventions under investigation include: Placebo (OTHER), veverimer daily (DRUG), veverimer every other day (DRUG).
Who is sponsoring clinical trial NCT07473713?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.